Internal Medicine, Pulmonary Disease · Sacramento, CA
NPI
1770697542
Since 2006
Specialty
Internal Medicine, Pulmonary Disease
Code 207RP1001X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
2825 J St, Ste 400
Sacramento, CA, 95816
Phone (916) 734-5360
Groups this clinician bills Medicare through
Medicare paid, 2024
$68K
1,058 services
Medicare patients, 2024
370
Average age 71
Drug cost, 2024
$12.6M
3,026 prescriptions
Company payments, 2025
$39K
From 7 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Namita Sood was code 99214 (office e&m - established), 304 times for 173 patients. In total Namita Sood billed 1,058 services in 35 codes, and Medicare paid $68K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-03-12.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 304 | 173 | $73.40 | $22K |
| 99232 Hospital E&M - Subsequent | Facility | 150 | 54 | $63.19 | $9,479 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 135 | 120 | $13.31 | $1,796 |
| 99215 Office E&M - Established | Office | 116 | 87 | $113.19 | $13K |
| 99233 Hospital E&M - Subsequent | Facility | 53 | 18 | $95.31 | $5,051 |
| 99222 Hospital E&M - Initial | Facility | 49 | 47 | $104.74 | $5,132 |
| 99213 Office E&M - Established | Office | 41 | 35 | $51.02 | $2,092 |
| G2212 Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 30 | 25 | $25.33 | $760 |
| 99204 Office E&M - New | Office | 27 | 27 | $90.27 | $2,437 |
| 99223 Hospital E&M - Initial | Facility | 16 | 16 | $139.32 | $2,229 |
| 94729 Pulmonary Function Testing | Office | 14 | 14 | $2.02 | $28.21 |
| 94726 Pulmonary Function Testing | Office | 14 | 14 | $2.72 | $38.13 |
| 94726 Pulmonary Function Testing | Facility | 13 | 13 | $2.90 | $37.68 |
| 94729 Pulmonary Function Testing | Facility | 13 | 13 | $2.14 | $27.88 |
| 99205 Office E&M - New | Office | 12 | 12 | $146.63 | $1,760 |
By year: 2022 $67K for 1,045 services; 2023 $64K for 807 services; 2024 $68K for 1,058 services.
Medicare prescription drug claims, 2024
In 2024, the drug Namita Sood prescribed most often to Medicare patients was Ambrisentan, with 360 prescriptions and refills. In total Namita Sood wrote 3,026 Medicare prescriptions that cost $12.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ambrisentan Generic | 360 | 398 | 39 | $1.2M |
| Ofev Nintedanib Esylate | 305 | 305 | 43 | $3.9M |
| Spironolactone Generic | 208 | 378 | 44 | $2,191 |
| Adempas Riociguat | 187 | 187 | 20 | $2.5M |
| Tadalafil Generic | 184 | 268 | 27 | $71K |
| Mycophenolate Mofetil Generic | 169 | 244 | 34 | $27K |
| Furosemide Generic | 165 | 304 | 44 | $941 |
| Fluticasone Propionate Generic | 117 | 211 | 57 | $1,914 |
| Pirfenidone Generic | 110 | 110 | 16 | $112K |
| Sildenafil Citrate Generic | 83 | 130 | 17 | $18K |
| Opsumit Macitentan | 73 | 73 | Under 11 | $884K |
| Torsemide Generic | 66 | 110 | 13 | $1,810 |
| Uptravi Selexipag | 61 | 69 | Under 11 | $1.2M |
| Letairis Ambrisentan | 56 | 64 | Under 11 | $819K |
| Loperamide Loperamide Hcl | 52 | 52 | 21 | $314 |
Brand drugs: - claims; generic drugs: 1,914 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Namita Sood $39K ($39K in general payments such as food, travel and fees) from 7 companies. The largest payer was United Therapeutics Corporation with $24K.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.